CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 409 filers reported holding CRISPR THERAPEUTICS AG in Q3 2023. The put-call ratio across all filers is 1.08 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $244,834 | -39.4% | 5,394 | -45.7% | 0.01% | -62.5% |
| Q4 2022 | $403,858 | -62.0% | 9,935 | -43.3% | 0.02% | -38.5% |
| Q2 2022 | $1,064,000 | -10.1% | 17,513 | -7.1% | 0.04% | -15.2% |
| Q1 2022 | $1,184,000 | +57.7% | 18,861 | +90.3% | 0.05% | +35.3% |
| Q4 2021 | $751,000 | +121.5% | 9,910 | +227.5% | 0.03% | +78.9% |
| Q3 2021 | $339,000 | -56.2% | 3,026 | -36.7% | 0.02% | -62.0% |
| Q2 2021 | $774,000 | -11.0% | 4,780 | -76.7% | 0.05% | -20.6% |
| Q1 2020 | $870,000 | +31.2% | 20,510 | +88.4% | 0.06% | +117.2% |
| Q4 2019 | $663,000 | +47.0% | 10,889 | -1.0% | 0.03% | +26.1% |
| Q3 2019 | $451,000 | – | 11,001 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |